title: Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects.
abstract: Plasma apolipoprotein A-IV (apoA-IV) levels are found elevated in hypertriglyceridemic patients. However, the relationship between plasma apoA-IV level and postprandial lipemia is not well known and remains to be elucidated. Thus, our objective was to study the relationship between plasma apoA-IV and postprandial TG after an oral fat load test (OFLT). Plasma apoA-IV was measured at fast and during an OFLT in 16 normotriglyceridemic, normoglucose-tolerant android obese subjects (BMI = 34.6 +/- 2.9 kg/m(2)) and 30 normal weight controls (BMI = 22.2 +/- 2.3 kg/m(2)). In spite of not statistically different fasting plasma TG levels in controls and obese patients, the former group showed an altered TG response after OFLT, featuring increased nonchylomicron TG area under the curve (AUC) compared with controls (516 +/- 138 vs. 426 +/- 119 mmol/l x min, P < 0.05). As compared to controls, obese patients showed increased apoA-IV levels both at fast (138.5 +/- 22.4 vs. 124.0 +/- 22.8 mg/l, P < 0.05) and during the OFLT (apoA-IV AUC: 79,833 +/- 14,281 vs. 68,176 +/- 17,463 mg/l x min, P < 0.05). Among the whole population studied, as among the control and obese subgroups, fasting plasma apoA-IV correlated significantly with AUC of plasma TG (r = 0.60, P < 0.001), AUC of chymomicron TG (r = 0.45, P < 0.01), and AUC of nonchylomicron TG (r = 0.62, P < 0.001). In the multivariate analysis, fasting apoA-IV level constituted an independent and highly significant determinant of AUC of plasma TG, AUC of chymomicron TG, AUC of nonchylomicron TG, and incremental AUC of plasma TG. In conclusion, we show a strong link between fasting apoA-IV and postprandial TG metabolism. Plasma fasting apoA-IV is shown to be a good marker of TG response after an OFLT, providing additional information on post-load TG response in conjunction with other known factors such as fasting TGs.
authors.affiliation: Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, CHU de Dijon, 21000 Dijon, France. bruno.verges@chu-dijon.fr
authors.forename: B
authors.initials: B
authors.lastname: Vergès
authors.forename: B
authors.initials: B
authors.lastname: Guerci
authors.forename: V
authors.initials: V
authors.lastname: Durlach
authors.forename: C
authors.initials: C
authors.lastname: Galland-Jos
authors.forename: J L
authors.initials: JL
authors.lastname: Paul
authors.forename: L
authors.initials: L
authors.lastname: Lagrost
authors.forename: P
authors.initials: P
authors.lastname: Gambert
mesh_terms: D000328:Adult; D000375:Aging; D001054:Apolipoproteins A / Q000097:blood*; D015415:Biomarkers; D001824:Body Constitution; D015992:Body Mass Index; D004041:Dietary Fats / Q000494:pharmacology; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D007700:Kinetics; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009765:Obesity / Q000097:blood*; D019518:Postprandial Period / Q000187:drug effects; D012727:Sex Characteristics; D014280:Triglycerides / Q000097:blood
chemical_list: D001054:Apolipoproteins A; D015415:Biomarkers; D004041:Dietary Fats; D008055:Lipids; D014280:Triglycerides; C022205:apolipoprotein A-IV